These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37565462)

  • 1. Differential cancer-specific survival with curative radiotherapy to the prostate for metastatic prostate cancer according to estimated survival by risk group.
    Shiota M; Terada N; Kimura T; Kitamura H; Kamoto T; Eto M;
    Int J Urol; 2023 Dec; 30(12):1197-1199. PubMed ID: 37565462
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer: too much dogma, not enough data.
    Raghavan D
    Cleve Clin J Med; 2008 Jan; 75(1):33-4. PubMed ID: 18236727
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: the relationship between prostate-specific antigen and prostate cancer risk: the prostate biopsy collaborative group.
    Walsh PC
    J Urol; 2011 Jan; 185(1):140. PubMed ID: 22082919
    [No Abstract]   [Full Text] [Related]  

  • 4. Early diagnosis of prostate cancer in the Western Cape.
    Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
    S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model to explain the 'vanishing' prostate -- the curative biopsy theory.
    Kommu S
    BJU Int; 2004 Oct; 94(6):939-40. PubMed ID: 15476547
    [No Abstract]   [Full Text] [Related]  

  • 6. Active surveillance for localized prostate cancer: update of a prospective single-center cohort.
    Thostrup M; Thomsen FB; Iversen P; Brasso K
    Scand J Urol; 2018 Feb; 52(1):14-19. PubMed ID: 28958194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer.
    Inaba K; Tsuchida K; Kashihara T; Umezawa R; Takahashi K; Okuma K; Murakami N; Ito Y; Igaki H; Sumi M; Nakayama Y; Shinoda Y; Hara T; Matsui Y; Komiyama M; Fujimoto H; Itami J
    J Radiat Res; 2021 May; 62(3):511-516. PubMed ID: 33822986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalation in localized prostate cancer: make no assumptions.
    Zietman AL
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):635-6. PubMed ID: 12377310
    [No Abstract]   [Full Text] [Related]  

  • 9. The interplay between obesity and the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer.
    Granieri MA; Freedland SJ
    BJU Int; 2013 Aug; 112(4):E272. PubMed ID: 23879911
    [No Abstract]   [Full Text] [Related]  

  • 10. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of density of prostate-specific antigen transitory zone in early diagnosis of prostate cancer].
    Topuzov ME
    Vopr Onkol; 2007; 53(3):295-7. PubMed ID: 18198610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.
    Vance SM; Stenmark MH; Blas K; Halverson S; Hamstra DA; Feng FY
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):940-6. PubMed ID: 22056069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy: in regard to Grimm et al., IJROBP 2001;51:31-40.
    Albrecht CH
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1429; author reply 1429. PubMed ID: 11955765
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial Comment to Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer.
    Yashi M
    Int J Urol; 2015 Jun; 22(6):561-2. PubMed ID: 25799888
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment to association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.
    Shimbo M
    Int J Urol; 2012 Aug; 19(8):747-8. PubMed ID: 22651131
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers.
    Pomykala KL; Herrmann K; Padhani AR; Hofman MS; Lalumera E; Fanti S
    J Nucl Med; 2022 Oct; 63(10):1480-1481. PubMed ID: 35680413
    [No Abstract]   [Full Text] [Related]  

  • 17. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period.
    Wu JN; Fish KM; Evans CP; Devere White RW; Dall'Era MA
    Cancer; 2014 Mar; 120(6):818-23. PubMed ID: 24258693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathological basis for elevation of serum prostate specific antigen].
    Xia TL; Deng FM; Feng T
    Zhonghua Yi Xue Za Zhi; 1994 May; 74(5):306-8, 327. PubMed ID: 7525028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.
    Autorino R; Perdonà S; Di Lorenzo G
    Urology; 2010 Nov; 76(5):1076; author reply 1076-7. PubMed ID: 21056255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.